Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05010772
Title Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center

acute myeloid leukemia


Decitabine and Cedazuridine

Decitabine and Cedazuridine + Ivosidenib

Decitabine and Cedazuridine + Gilteritinib

Decitabine and Cedazuridine + Enasidenib

Decitabine and Cedazuridine + Venetoclax

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.